<DOC>
	<DOCNO>NCT00003757</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy consist rituximab treat patient refractory recurrent hairy cell leukemia follow cladribine therapy .</brief_summary>
	<brief_title>Rituximab Treating Patients With Refractory Recurrent Hairy Cell Leukemia Following Cladribine Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate complete partial remission , remission duration , relapse free survival treatment rituximab patient refractory recurrent hairy cell leukemia previously receive cladribine . - Determine acute long term toxicity rituximab patient . OUTLINE : This open-label , multicenter study . Patients receive rituximab IV several hour week 4 week . Patients follow every 3 month 3 year every 6 month thereafter . PROJECTED ACCRUAL : A total 8-25 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hairy cell leukemia ( HCL ) Classic HCL Hairy cell bone marrow and/or peripheral blood coexpress CD20/CD25 CD20/CD11c , and/or positive tartrate resistant acid phophatase ( TRAP ) Prolymphocytic HCL variant Lymphoid cell bone marrow and/or peripheral blood morphology intermediate typical hairy cell prolymphocytes , coexpress CD20/CD11c lack CD25 expression , negative TRAP Progressive recurrent disease prior treatment cladribine Greater 1 month since standard dose cladribine OR Greater 3 month since low dose cladribine PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.3 mg/dL Cardiovascular : No serious cardiac disease Other : No acute chronic infection HIV negative No psychosis Not pregnant nursing No prior concurrent malignancy except carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Recovered prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered prior therapy No concurrent cytoreductive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
</DOC>